This article was originally published in The Gray Sheet
Private placement of 3.7 mil. shares nets $26 mil. to fund a two-year capacity expansion project for the firm's r/LS red blood cell filtration system. The expansion is anticipated to result in a greater-than-ten-fold increase in production capability in order to meet demand for leukoreduced blood products. The project will commence in the second quarter and further the American Red Cross goal of 100% leukoreduction by the end of 2000
You may also be interested in...
Beiersdorf and former owner Bayer are on the verge of settling a proposed class action in California’s Northern District challenging “mineral-based” claims on Coppertone sunscreens that also contain chemical UV filters. However, the parties will have to try again with their proposed terms.
The MHRA is in listening mode as it gathers feedback to shape the UKCA marking for medical devices. See what Phil Brown, regulatory director of the Association of British HealthTech Industries, said about it here.
Following a memorable cancer drug advisory panel meeting where FDA explained how accelerated approvals may be more at risk due to changing standard of care, ChemoCentryx’s ANCA-vasculitis treatment runs into trouble because of another drug’s changing indication during their Phase III study.